651 related articles for article (PubMed ID: 16332942)
1. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
2. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
4. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
11. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
12. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
[TBL] [Abstract][Full Text] [Related]
13. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
14. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
15. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
16. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
Glaspy J
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
20. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
Folloder J
Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
